Dr Noor Almheiri, Director of the Mental Health Department at EHS, highlighted that maintaining treatment continuity is a major challenge in chronic mental health conditions, noting that BYANNLI provides an advanced option to support stability and improve patients’ quality of life.

Improved patient adherence and clinical results

EHS said the introduction of the treatment aligns with global developments in mental healthcare and supports more effective follow-up, improved treatment adherence, and efficient use of healthcare resources.

Al Amal Psychiatric Hospital has reported strong results from long-acting treatments, including reduced readmission rates below 1%, treatment adherence of 93%, and significant improvement in psychiatric symptoms among 93% of patients.

Through the introduction of BYANNLI, Emirates Health Services (EHS) continues to strengthen its focus on innovative, integrated and sustainable healthcare services while supporting the UAE’s vision for a world-class healthcare system.